United Therapeutics(UTHR) - 2023 Q4 - Earnings Call Presentation

Financial Performance - Total revenue reached $615 million, a 25% year-over-year increase[34] - Tyvaso revenue was $351 million, representing a 45% year-over-year increase[34] - Remodulin revenue was $115 million, a 6% year-over-year increase[34] - Orenitram revenue was $84 million, an 11% year-over-year increase[34] - Unituxin revenue was $54 million, a 48% year-over-year increase[34] - The company's operating cash flow for FY23 was $978 million[24] - The company has $4.9 billion in cash, cash equivalents, and marketable investments[24] Tyvaso DPI - Sagard Healthcare Partners acquired a 1% royalty interest in Tyvaso DPI from MannKind for $150 million plus other milestones[13] - The company highlights an implied Tyvaso DPI revenue valuation of over $15 billion based on a deal executed after an appeals court ruling, where a 1% royalty equated to $150 million[114] Clinical Trials and Development - TETON 1 and TETON 2 studies for Idiopathic Pulmonary Fibrosis (IPF) are approximately 70% enrolled[28] - The ADVANCE OUTCOMES study for PAH is targeted for trial completion in 2025[31]